Ena 713 Free Base en es it fr

Ena 713 Free Base Brand names, Ena 713 Free Base Analogs

Ena 713 Free Base Brand Names Mixture

  • No information avaliable

Ena 713 Free Base Chemical_Formula

C14H22N2O2

Ena 713 Free Base RX_link

http://www.rxlist.com/cgi/generic2/rivastig.htm

Ena 713 Free Base fda sheet

Ena_713_Free_Base FDA

Ena 713 Free Base msds (material safety sheet)

Ena 713 Free Base Synthesis Reference

No information avaliable

Ena 713 Free Base Molecular Weight

250.337 g/mol

Ena 713 Free Base Melting Point

No information avaliable

Ena 713 Free Base H2O Solubility

No information avaliable

Ena 713 Free Base State

Solid

Ena 713 Free Base LogP

2.611

Ena 713 Free Base Dosage Forms

Capsule; Solution

Ena 713 Free Base Indication

For the treatment of mild to moderate Alzheimer's disease.

Ena 713 Free Base Pharmacology

Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Rivastigmine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Pathological changes in Dementia of the Alzheimer type involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways are thought to be intricately involved in memory, attention, learning, and other cognitive processes. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact.

Ena 713 Free Base Absorption

No information avaliable

Ena 713 Free Base side effects and Toxicity

No information avaliable

Ena 713 Free Base Patient Information

Caregivers should be advised of the high incidence of nausea and vomiting associated with the use of the drug along with the possibility of anorexia and weight loss. Caregivers should be encouraged to monitor for these adverse events and inform the physician if they occur. It is critical to inform caregivers that if therapy has been interrupted for more than several days, the next dose should not be administered until they have discussed this with the physician.

Ena 713 Free Base Organisms Affected

Humans and other mammals